Innovative applications of 3D printing in personalized medicine and complex drug delivery systems
Kapoor DU., Pareek A., Uniyal P., Prajapati BG., Thanawuth K., Sriamornsak P.
Narrative Review, published in iScience (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- iScience (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41035685
- PMCID
- PMC12481080
- DOI
- 10.1016/j.isci.2025.113505
- Citations
- 3
Abstract (original English)
Three-dimensional (3D) printing, or additive manufacturing, is transforming pharmaceutical and biomedical fields by enabling personalized medicine. This review highlights advances in 3D printing for customized drug delivery systems, including patient-specific dosage forms, multidrug polypills, and implantable devices that improve adherence and therapeutic outcomes-especially for pediatric and geriatric populations. The intersection of 3D printing with regenerative medicine is also explored, focusing on bioprinting technologies, stem cell-laden scaffolds, and smart biomaterials such as hydrogels and bioinks for localized therapy and tissue repair. These strategies reflect an expanded vision of personalized medicine, merging individualized pharmacotherapy with tissue engineering. Additionally, the review discusses the integration of artificial intelligence, nano-enabled platforms, and decentralized pharmaceutical manufacturing to accelerate development and access. Key regulatory and technical challenges are outlined, along with future directions to promote the clinical translation and scalability of 3D-printed pharmaceutical and regenerative systems.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.